

<p>94-283250/35 B07 (B05) MITU 93.01.14 MITSUBISHI KASEI CORP *JP 06211645-A 93.01.14 93JP-004810 (94.08.02) A61K 9/127, 9/14, 47/30 Freeze-dried liposome preparation - contains cyclic inulooligosaccharide as stabiliser C94-129180</p>	<p>B(4-C2X, 12-M6, 12-M11F)</p>
<p>Freeze-dried liposome preparation includes cyclic inulooligosaccharide. The prep. pref. contains another saccharide gp. and/or peptide gp. Cyclic inulooligo saccharide comprises pref. cyclic structure of 2-8 fructose by binding beta-2,1. Saccharide is pref. selected from trehalose, saccharose, lactose, maltose, glucose and fructose. Peptide gp. is pref. selected from gelatin, alubumin and casein. Membrane substances of liposome are phospholipid e.g. phosphatidylcholine, phosphatidylethanol amine, phosphatidylinositol, phosphatidylserine and sphingomyeline derived from egg yolk, soybeans, other animals and plants; dipalmitoylphosphatidylcholine (DPPC), distearylphosphatidylcholine (DSPC) and dipalmitoylphosphatidylethanol amine (DPPE). Drugs sealed in liposome are anti-cancer agent e.g. adriamycin; antiviral agent e.g. interferon and peptide hormone, e.g. insulin and calcitonin; enzymatic agent, e.g. alkali phosphatase; amino succaride</p>	<p>antibiotics, e.g. gentamicin and streptomycin. The wt. ratio of cyclic inulooligo saccharide to lipid is 1/10-2/1, pref. 1/10-1/1. The wt. ratio of other saccharide gp. to cyclic inulooligo saccharide is 1/2-1/1, and the wt. ratio of peptide gp. to cyclic inulooligo saccharide is 1/5-1/2. The wt. ratio of cyclic inulooligo saccharide, or total amt. of other saccharide gp. and peptide gp. to lipid is 1/10-1/1.</p> <p>USE/ADVANTAGE - The freeze-dried liposome prep. is stably preserved over a long period of time due to the addn. of cyclic inulooligo saccharide as stabiliser. The dia. of the liposome is not changed even when dissolved in water in use, almost completely keeping the drug sealed in a liposome. (4pp Dwg.No.0/0)</p>